To compare the efficacy of the addition of a therapeutic education program combined with nursing phone follow-up, compared to conventional management alone, on the management of adverse events (AEs) related to adjuvant hormone therapy during the first year of treatment in patients with non-metastatic breast cancer.
Female patients aged 18 to 75 years inclusive
Patients with non-metastatic breast cancer for whom adjuvant hormone therapy (anti-oestrogen or anti-aromatase) is indicated, depending on the decision of the multidisciplinary consultation meeting.
Performance status (ECOG) ≤ 2
Patient able to read and understand French (common use)
Patient with metastatic cancer (stage IV)
Patient undergoing neoadjuvant hormone therapy
Patient who started hormone therapy prior to inclusion in the study
Patient with a history of other cancer treated by radiotherapy, chemotherapy or hormone therapy, with an end of treatment less than 2 years ago.
Centre Hospitalier Emile Roux
Lead sponsor
University Hospital, Clermont-Ferrand
Collaborator
Walisco
Collaborator